You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

~ Buy the VICTOZA (liraglutide recombinant) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VICTOZA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VICTOZA

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00993720 ↗	Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes	Completed	Hvidovre University Hospital	Phase 2/Phase 3	2009-10-01	The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
NCT01029886 ↗	Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	Completed	Eli Lilly and Company	Phase 3	2010-01-01	No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
NCT01029886 ↗	Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	Completed	AstraZeneca	Phase 3	2010-01-01	No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for VICTOZA

Condition Name

Chart
Table

Condition Name for VICTOZA
Intervention	Trials
Type 2 Diabetes	27
Type 2 Diabetes Mellitus	19
Obesity	18
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for VICTOZA
Intervention	Trials
Diabetes Mellitus	69
Diabetes Mellitus, Type 2	61
Diabetes Mellitus, Type 1	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for VICTOZA

Trials by Country

Map
Table

Trials by Country for VICTOZA
Location	Trials
United States	168
China	29
Canada	25
Denmark	21
Germany	10
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for VICTOZA
Location	Trials
California	13
New York	11
Texas	9
Florida	8
Ohio	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for VICTOZA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for VICTOZA
Clinical Trial Phase	Trials
Phase 4	45
Phase 3	22
Phase 2/Phase 3	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for VICTOZA
Clinical Trial Phase	Trials
Completed	80
Recruiting	12
Unknown status	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VICTOZA

Sponsor Name

Chart
Table

Sponsor Name for VICTOZA
Sponsor	Trials
Novo Nordisk A/S	41
University of Copenhagen	5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for VICTOZA
Sponsor	Trials
Other	168
Industry	61
NIH	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.